La cadena de opciones muestra datos clave de las opciones de acciones de Biofrontera a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Biofrontera..

Biofrontera (NASDAQ:BFRI) Bolsa, Cadena de Opciones

Biofrontera

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.

Biofrontera Inc

JP Morgan analyst Michael Cho assumes Forge Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRGE#NYSE">FRGE</a>) with a Neutral rating and announces Price Target of $18.

News

Price Target

Initiation

Analyst Ratings

FRGE

JP Morgan Assumes Forge Global Holdings at Neutral, Announces Price Target of $18

Avis Budget Announced That Its Wholly-owned Subsidiaries Intend, Subject To Market And Other Customary Conditions, To Offer $500M Aggregate Principal Amount Of Senior Notes Due 2032 In A Private Offering

OpenAI chief Sam Altman describes Airbnb CEO Brian Chesky as someone who loves to express his individuality and influence through his work as a founder, a quality he thinks comes through during Airbnb&#8217;s launches.
What Happened: Altman lit up X after Chesky posted a teaser for Airbnb's sweeping overhaul, writing, "Brian is the most auteur founder of this generation, and it really shines through in how he does launches!" and later adding, "the new app design is so great."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">brian is the most auteur founder of this generation, and it really shines through in how he does launches! <a href="https://t.co/BSgjUsCMzq">https://t.co/BSgjUsCMzq</a>
&mdash; Sam Altman (@sama) <a href="https://twitter.com/sama/status/1922372362420256960?ref_src=twsrc%5Etfw">May 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Altman's praise landed hours after Chesky unveiled Airbnb's radical shift in the direction of being an &#8220;everything app.&#8221; "Now, you can Airbnb more than an Airbnb," Chesky told a Tuesday crowd, promising to turn every trip or hometown weekend into a curated itinerary.
Chesky introduced the three pillars for the platform: Airbnb Services, a re-engineered Airbnb Experiences, and an all-new app tying them together. The headline addition, Airbnb Services, lets users in 260 cities book in-home chefs, massages, personal trainers and even makeup artists, matching perks long monopolized by hotels.
See also: <a href="https://www.benzinga.com/markets/equities/25/05/45402695/teslas-robotaxi-plans-under-federal-scrutiny-ahead-ff-austin-launch-as-elon-musk-vows-nationwide-rollout-by-year-end">Tesla&#8217;s Robotaxi Plans Under Federal Scrutiny Ahead Ff Austin Launch As Elon Musk Vows Nationwide Rollout By Year-End</a>
The rebooted Experiences hub ditches bus-tour clichés for five lanes—history &amp; culture, food &amp; drink, nature &amp; outdoors, art &amp; design, and fitness &amp; wellness — ranging from restoring Notre Dame with its architects to ramen lessons from Michelin-star chefs.
Airbnb is also rolling out Originals, limited-slot events hosted by names like Megan Thee Stallion and NFL MVP Patrick Mahomes.
A ground-up app redesign was also launched at the event, which features countdown widgets, interactive icons and AI-driven suggestions into a single itinerary view that mashes lodging, services and experiences.
Why It Matters: Wall Street analysts <a href="https://www.benzinga.com/25/05/45175845/wall-street-reacts-as-airbnb-eyes-growth-amid-us-slowdown-details">told Benzinga</a> the summer release is meant to open new revenue lanes as Airbnb's core bookings mature, even as regulatory and hotel competition pressures persist.
Altman, in a blog post earlier this year, publicly stated that Chesky and SV Angel founder Ron Conway did "incredible and gigantic amounts of work" helping him during his <a href="https://www.benzinga.com/news/23/12/36171063/what-really-happened-with-sam-altman-getting-fired-as-openai-ceo-new-details-emerge">brief ouster from OpenAI</a> in November 2023. Altman added that the pair "stopped me from making several mistakes," and suggested OpenAI might not still be standing without their support.
Photo by Boumen Japet via Shutterstock
Read next: <a href="https://www.benzinga.com/news/25/05/45403040/jeff-bezos-became-a-billionaire-after-taking-this-leap-of-faith-would-you-have-the-stomach-for-his-regret-minimization-strategy">Jeff Bezos Became A Billionaire After Taking This Leap Of Faith: Would You Have The Stomach For His &#8216;Regret-Minimization&#8217; Strategy?</a>

Tech

Brian Chesky Shares Promo For Airbnb's Biggest Change In Decades, Sam Altman Calls Him 'The Most Auteur Founder Of This Generation'

MediPharm Labs (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MEDIF#OTC">MEDIF</a>) reported quarterly sales of $7.53 million which missed the analyst consensus estimate of $10.54 million by 28.59 percent. This is a 3.85 percent increase over sales of $7.25 million the same period last year.

Earnings

Earnings Misses

MEDIF

MediPharm Labs Q1 Sales $7.53M Miss $10.54M Estimate

<ul class="wp-block-list">
<li>Walgreens has plans to expand its use of robot-powered micro-fulfillment centers</li>
<li>The centers currently serve 4,800 stores, and fill more than 16 million prescriptions each month</li>
<li>The push for automation comes as Walgreens prepares to go private in a deal with Sycamore Partners</li>
</ul>
Walgreens will be expanding its use of prescription-filling robots, <a href="https://www.cnbc.com/2025/05/11/walgreens-doubles-down-on-robots-to-fill-prescriptions-amid-turnaround.html">CNBC</a> reports.
The pharmacy chain began using micro-fulfillment centers in 2021 before pausing the program in 2023 to focus on feedback and improvement. Now, it&#8217;s working to add more in order to free up time for pharmacy staff, reduce time spent on routine tasks, and eliminate inventory waste.
The robot-powered centers fill thousands of prescriptions for patients who use medication to manage conditions like diabetes and high blood pressure. With those tasks automated, Walgreens told CNBC its pharmacy staff will have more time to interact directly with patients and perform clinical services like vaccinations and testing.
Don't Miss:
<ul class="wp-block-list">
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
</ul>
The company told CNBC it hopes to have 11 micro-fulfillment centers serving 5,000 locations by the end of the year. In February, there were 4,800 stores that utilized the micro-fulfillment centers. On average, these centers handled 40% of the prescription volume at the individual locations, Walgreens says, which translates to about 16 million prescriptions filled each month across all serviced stores.
Kayla Heffington, Walgreens' pharmacy operating model vice president, told CNBC that the company's investment in automation is already paying off. The micro-fulfillment centers have generated $500 million in savings through their increased efficiency and reduction of excess inventory. Stores that use the centers are also administering 40% more vaccines than those that aren't, increasing profits.
"Right now, [the micro-fulfillment centers] are the backbone to really help us offset some of the workload in our stores, to obviously allow more time for our pharmacists and technicians to spend time with patients," Rick Gates, Walgreens' chief pharmacy officer, told CNBC. "It gives us a lot more flexibility to bring down costs, to increase the care and increase speed to therapy – all those things."
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a>
Gates added that he sees the micro-fulfillment centers as a competitive advantage for Walgreens, because many independent pharmacies and larger rivals don't have the centralized support. However, many of Walgreens' major competitors, like Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>), Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>), and Albertsons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>), already have, or are testing, their own versions of the micro-fulfilment facilities.&nbsp;
There are, of course, risks that come with using these micro-fulfillment centers, like a reliance on sophisticated robotics that can cause major disruptions if errors occur. But for Walgreens, the rewards heavily outweigh the risks.
Heffington told CNBC that the automated locations have helped reduce prescription fulfillment costs by nearly 13% year over year, and have increased prescription volume by 126%. The centers also allow the company to have real-time data on all prescription fulfillments, enabling its employees to provide better customer service.&nbsp;
The renewed push for automation comes as Walgreens prepares to go private in a <a href="https://investor.walgreensbootsalliance.com/news-releases/news-release-details/walgreens-boots-alliance-enters-definitive-agreement-be-acquired">$10 billion deal with Sycamore Partners</a>. The buyout is expected to be complete by the end of the year.&nbsp;
Read Next:
<ul class="wp-block-list">
<li>The team behind $6B+ in licensing deals is now building the next billion-dollar IP empire — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">invest early at $2.25/share.</a></li>
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
</ul>
Image: Shutterstock

Personal Finance

Walgreens To Expand Use Of Prescription-Filling Robots, Cites $500 Million In Savings As Motive

Market-Moving Exclusives

Exclusives

CHRO

EXCLUSIVE: Channel Therapeutics Tells Benzinga Co. Announces Results For The Treatment Of Eye Pain Using NaV1.7 Inhibitor In Multiple Preclinical In Vivo Models

WIIM

RCAT

Red Cat Holdings shares are trading higher after the company announced the expansion of its multi-domain Family of Systems with a new line of Unmanned Surface Vessels.

VERV

Verve Therapeutics shares are trading higher after the company reported a year-over-year increase for Q1 EPS results.

ARCO

Arcos Dorados Holdings shares are trading lower after the company reported mixed Q1 financial results.

GRAL

GRAIL shares are trading lower after the company reported mixed Q1 financial results.

ZYNLONTA&#xAE;&nbsp;plus glofitamab (COLUMVI&#xAE;) demonstrated&nbsp;ORR of 95.5% and CR of 90.9%, among 22 evaluable patients with relapsed/refractory DLBCL
Safety and tolerability data were consistent with the known profiles of each agent
Updated data to be shared during poster presentation at EHA2025 on Saturday, June 14 at 12:30 p.m. ET and oral presentation at ICML on Friday, June 20 at 9:00 a.m. ET
LAUSANNE, Switzerland, May 14, 2025 /PRNewswire/ --&nbsp;ADC Therapeutics SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced data presentations from the LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA (loncastuximab tesirine-lpyl) in combination with glofitamab in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). Updated results will be shared at the European Hematology Association 2025 Congress (EHA2025) taking place in Milan, Italy with an oral encore presentation at the 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland. Updated LOTIS-5 safety run-in data evaluating the combination of ZYNLONTA plus rituximab (Lonca-R) will also be featured at EHA2025.

ADCT

ADC Therapeutics Presents Data From LOTIS-7 Phase 1B Clinical Trial Evaluating ZYNLONTA In Combination With Glofitamab In Patients With r/r DLBCL

Jefferies analyst Philippe Houchois downgrades Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) from Buy to Hold and maintains the price target from $16 to $16.

Downgrades

RIVN

Jefferies Downgrades Rivian Automotive to Hold, Maintains Price Target to $16

Contracts

Jacobs Was Selected As The Integrated Delivery Partner For Marinus Link, An Approximately 214 Mile (345-kilometer) Undersea And Underground High-voltage Direct Current (Hvdc) Electricity And Data Interconnector

Needham analyst Bernie McTernan reiterates Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) from Hold to Hold.

Reiteration

ABNB

Needham Reiterates Hold on Airbnbto Hold

Jefferies analyst Ashley Helgans upgrades PVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) from Hold to Buy and raises the price target from $70 to $105.

Upgrades

Jefferies Upgrades PVH to Buy, Raises Price Target to $105

Nissan Motor Co. Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NSANY#OTC">NSANY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NSANF#OTC">NSANF</a>) announced major steps to reconfigure its global operations after a challenging financial year. The company said on Tuesday that it will slash thousands of jobs and close almost half of its production plants across the globe, as part of a multi-year restructuring plan targeted towards stabilizing its bottom line.
What Happened: The company shared plans to terminate nearly 15% of its workforce, which entails approximately 20,000 employees, by fiscal year 2027. This includes the 9,000 job cuts announced earlier. In addition, Nissan will also shrink its global manufacturing footprint, reducing the number of factories from 17 to 10 over two years.
Last week, reports emerged that the <a href="https://www.benzinga.com/news/25/05/45316137/nissan-scraps-11-billion-ev-battery-plant-eyes-cost-cuts-to-survive-report">company is canceling its plans</a> to establish a $1.1 billion electric vehicle battery factory in Kitakyushu, Japan.
See Also: <a href="https://www.benzinga.com/25/05/45250949/tech-layoffs-get-the-headlines-but-its-uncle-sam-doge-whos-bleeding-workers-in-2025">Intel, Meta Get The Headlines, But It&#8217;s Uncle Sam (DOGE) Who&#8217;s Bleeding Workers In 2025</a>
Why It Matters: Nissan faced a $4.5 billion loss in 2024, citing rising variable costs and ongoing global turmoil. "In the face of challenging FY24 performance and rising variable costs, compounded by an uncertain environment, we must prioritize self-improvement with greater urgency and speed," said CEO Ivan Espinosa. The company also noted it would prioritize U.S.-made products and move operations to <a href="https://www.benzinga.com/news/25/05/45316137/nissan-scraps-11-billion-ev-battery-plant-eyes-cost-cuts-to-survive-report">sidestep tariff-related pressures</a>.
"We are taking a prudent approach to reassess our targets and actively seek every possible opportunity to implement and ensure a robust recovery," Espinosa added.
Nissan was not the only major company to announce layoffs on Tuesday. Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) shared on the same day that it will cut <a href="https://www.benzinga.com/markets/equities/25/05/45398101/microsoft-to-cut-6000-jobs-in-global-restructuring-joins-meta-and-amazon-in-trimming-workforce-amid-ai-driven-shift">6,000 jobs worldwide</a>, amounting to about 3% of its total workforce.
Price Action: Nissan Motor stock closed at 354 JPY ($2.42) on the Tokyo Stock Exchange on Wednesday, down 0.70% for the day. Year to date, the stock has declined 25.44%.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/market-summary/25/05/45399940/warren-buffett-shows-how-patience-pays-98-of-his-160-billion-wealth-came-after-turning-65-thanks-the-power-of-compound-interest">Warren Buffett Shows How Patience Pays: 98% Of His $160 Billion Wealth Came After Turning 65, Thanks The Power Of &#8216;Compound Interest&#8217;</a></li>
</ul>
Image Via Shutterstock

Asia

Equities

Markets

General

MSFT

NSANF

NSANY

Nissan To Cut 20,000 Jobs, Shut 7 Plants Globally In Major Restructuring After $4.5 Billion Annual Loss

TSAT

Telesat And Arab Satellite Communications Organization Announced The Companies Have Successfully Negotiated And Signed A Term Sheet For A Multi-Gbps Capacity Pool Of Telesat Lightspeed Connectivity Services

Needham analyst Quinn Bolton reiterates Pixelworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXLW#NASDAQ">PXLW</a>) with a Buy and maintains $1.5 price target.

PXLW

Needham Reiterates Buy on Pixelworks, Maintains $1.5 Price Target

LAVA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVTX#NASDAQ">LVTX</a>) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.38) by 65.79 percent. This is a 550 percent decrease over losses of $(0.02) per share from the same period last year.

Earnings Beats

LVTX

LAVA Therapeutics Q1 EPS $(0.13) Beats $(0.38) Estimate

Needham analyst Mike Matson upgrades Establishment Labs Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESTA#NASDAQ">ESTA</a>) from Hold to Buy and announces $48 price target.

ESTA

Needham Upgrades Establishment Labs Hldgs to Buy, Announces $48 Price Target

Press Releases

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

Events

Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025

Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk

Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update

Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis

Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025

Comments

Biofrontera

Biofrontera (BFRI) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL